🇺🇸 FDA
Pipeline program

Early recognition of progressive lung fibrosis in systemic rheumatic diseases: a characterization of the pulmonary environment through extracellular vesicles, advanced and functional imaging

COOPERATION 2.0

Phase 2 other active

Quick answer

Early recognition of progressive lung fibrosis in systemic rheumatic diseases: a characterization of the pulmonary environment through extracellular vesicles, advanced and functional imaging for Patients with connective tissue diseases at high risk of interstial lung disease is a Phase 2 program (other) at Fondazione Telethon ETS with 1 ClinicalTrials.gov record(s).

Program details

Company
Fondazione Telethon ETS
Indication
Patients with connective tissue diseases at high risk of interstial lung disease
Phase
Phase 2
Modality
other
Status
active

Clinical trials